Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (VKTX) reported its Q3 2021 financial results with a net loss of $13.2 million ($0.17 per share), compared to a loss of $9.3 million ($0.13 per share) in Q3 2020. The increase in loss was attributed to rising research and development expenses, now totaling $10.8 million, primarily for clinical studies. Viking is advancing its clinical pipeline, including ongoing Phase 2b VOYAGE trial for VK2809 in NASH and Phase 1b trial for VK0214 in X-ALD. The company ended Q3 with $216 million in cash, positioning it well for future developments.
Viking Therapeutics (NASDAQ: VKTX) presented preclinical data on dual GLP-1/GIP agonists at ObesityWeek 2021. The findings demonstrate significant weight loss and metabolic improvements in diet-induced obese mice, with weight reductions of up to 28%, and enhanced glucose and insulin responses compared to vehicle and semaglutide. The study results support the efficacy of dual agonists and provide a foundation for a forthcoming Phase 1 trial of a lead candidate. CEO Brian Lian emphasized the potential of these compounds in advancing treatment for metabolic disorders.
Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical firm, will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company is developing oral therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK2809 has shown efficacy in reducing LDL-C and liver fat in prior studies. The firm holds exclusive rights to five therapeutic programs from Ligand Pharmaceuticals.
Viking Therapeutics (NASDAQ: VKTX) announced the presentation of promising preclinical data on novel dual agonists targeting GLP-1 and GIP receptors at ObesityWeek 2021, occurring from November 1-5, 2021. Results from studies in diet-induced obese mice highlight significant weight loss and improved metabolic profiles. The poster presentations will be led by Kader Yagiz, Ph.D. This research could enhance Viking's pipeline of therapies for metabolic and endocrine disorders, further supporting its clinical programs, including VK2809 for NASH and fibrosis.
Viking Therapeutics (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The virtual presentation is scheduled for 11:00 – 11:20 a.m. Eastern. Viking is focused on developing innovative therapies for metabolic and endocrine disorders, including VK2809, a selective thyroid hormone receptor beta agonist currently in Phase 2b for NASH. The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in four upcoming investor conferences. The events include Citi's 16th Annual Biopharma Virtual Conference (Sept 8-10), H.C. Wainwright's 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 27-30). Presentations will be available online, and webcasts will follow. Viking focuses on innovative therapies for metabolic disorders, with key programs including VK2809 and VK0214 currently in clinical trials.
Viking Therapeutics (VKTX) reported its second-quarter 2021 financial results, showing a net loss of $15.4 million or $0.20 per share, up from $9.6 million or $0.13 per share in Q2 2020. The firm is advancing its clinical programs, including VK2809 for NASH, with promising interim results. The Phase 1 study of VK0214 in healthy volunteers met its primary objectives, leading to the initiation of a Phase 1b trial for X-ALD patients. Viking ended the quarter with a strong cash position of $228.3 million, supporting its ongoing studies and upcoming milestones.
Viking Therapeutics (NASDAQ: VKTX) will announce its second quarter 2021 financial results after the market close on July 28, 2021. A conference call will follow at 4:30 p.m. Eastern Time, where the company will discuss the results and corporate updates. Investors can participate by calling designated numbers or listening via webcast. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, with programs including VK2809 for non-alcoholic steatohepatitis and VK0214 for X-linked adrenoleukodystrophy.
Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 1b clinical trial for VK0214, a novel thyroid hormone receptor beta agonist, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The trial, which is randomized and double-blind, targets adult male patients with the adrenomyeloneuropathy form of X-ALD. Key objectives include evaluating VK0214's safety, tolerability over 28 days, and its efficacy in lowering plasma levels of very long-chain fatty acids. VK0214, having completed an earlier successful Phase 1 study, has shown promising safety and pharmacokinetics.
Viking Therapeutics (NASDAQ: VKTX) announced positive results from its Phase 1 clinical trial of VK0214, a thyroid receptor beta agonist targeting X-linked adrenoleukodystrophy (X-ALD). The study confirmed VK0214's safety and tolerability with no serious adverse events and a favorable pharmacokinetic profile. Notably, VK0214 significantly reduced low-density lipoprotein cholesterol (LDL-C), triglycerides, and apolipoprotein B, indicating potential therapeutic benefits. Viking plans to commence a Phase 1b study in X-ALD patients soon.